Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 trial assessing safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy GAL-101

Next Previous
Trial Profile

A Phase 1 trial assessing safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy GAL-101

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GAL 101 (Primary)
  • Indications Alzheimer's disease; Dry age-related macular degeneration; Glaucoma
  • Focus Adverse reactions
  • Sponsors Thea Open Innovation

Most Recent Events

  • 06 May 2025 According to Galimedix Therapeutics media release, the company announced completion of the single ascending dose (SAD) part of the Phase 1 study. The company is on track to complete later this year.
  • 30 Dec 2024 New trial record
  • 06 Dec 2024 According to Galimedix Therapeutics media release, company initiates phase 1 trial of oral GAL-101

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top